Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human.

Halpin RA, Ulm EH, Till AE, Kari PH, Vyas KP, Hunninghake DB, Duggan DE.

Drug Metab Dispos. 1993 Nov-Dec;21(6):1003-11.

PMID:
7905377
2.

Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats.

Lin JH, Chen IW, Duggan DE.

Drug Metab Dispos. 1992 Jul-Aug;20(4):473-8.

PMID:
1356720
3.

Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals.

Lin JH, Duggan DE, Chen IW, Ellsworth RL.

Drug Metab Dispos. 1991 Sep-Oct;19(5):926-32.

PMID:
1686238
4.
5.

Dose-dependent pharmacokinetics of MK-417, a potent carbonic anhydrase inhibitor, in rabbits following single and multiple doses.

Lin JH, Chen IW, Ulm EH, Gehret JR, Duggan DE.

Drug Metab Dispos. 1990 Nov-Dec;18(6):836-41.

PMID:
1981525
6.

In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase.

Vickers S, Duncan CA, Vyas KP, Kari PH, Arison B, Prakash SR, Ramjit HG, Pitzenberger SM, Stokker G, Duggan DE.

Drug Metab Dispos. 1990 Jul-Aug;18(4):476-83.

PMID:
1976071
7.
8.

Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug.

Vickers S, Duncan CA, Chen IW, Rosegay A, Duggan DE.

Drug Metab Dispos. 1990 Mar-Apr;18(2):138-45.

PMID:
1971563
9.

Physiological disposition of HMG-CoA-reductase inhibitors.

Duggan DE, Vickers S.

Drug Metab Rev. 1990;22(4):333-62. Review. No abstract available.

PMID:
2253556
10.

The physiological disposition of lovastatin.

Duggan DE, Chen IW, Bayne WF, Halpin RA, Duncan CA, Schwartz MS, Stubbs RJ, Vickers S.

Drug Metab Dispos. 1989 Mar-Apr;17(2):166-73.

PMID:
2565206
11.

Differential renal handling of angiotensin-converting enzyme inhibitors enalaprilat and lisinopril in rats.

Lin JH, Chen IW, Ulm EH, Duggan DE.

Drug Metab Dispos. 1988 May-Jun;16(3):392-6.

PMID:
2900730
12.
13.

Differential effects of phenobarbital on ester and ether glucuronidation of diflunisal in rats.

Lin JH, Chen IW, Ulm EH, Duggan DE.

J Pharmacol Exp Ther. 1987 Sep;242(3):1013-8.

PMID:
3656106
14.

Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.

Lin JH, Cocchetto DM, Duggan DE.

Clin Pharmacokinet. 1987 Jun;12(6):402-32. Review.

PMID:
3301150
15.

Urinary excretion kinetics of famotidine in rats.

Lin JH, Los LE, Ulm EH, Duggan DE.

Drug Metab Dispos. 1987 Mar-Apr;15(2):212-6.

PMID:
2882981
16.

Comparative effects of H2-receptor antagonists on drug interaction in rats.

Lin JH, Cocchetto DM, Yeh KC, Duggan DE.

Drug Metab Dispos. 1986 Nov-Dec;14(6):649-53.

PMID:
2877821
17.

Possible mechanisms for reduced plasma clearance of diflunisal in rat experimental renal failure.

Lin JH, Ulm EH, Duggan DE.

J Pharmacol Exp Ther. 1986 Sep;238(3):978-84.

PMID:
3746671
18.

Dose-dependent pharmacokinetics of diflunisal in rats: dual effects of protein binding and metabolism.

Lin JH, Hooke KF, Yeh KC, Duggan DE.

J Pharmacol Exp Ther. 1985 Nov;235(2):402-6.

PMID:
4057077
21.

Bioanalysis and disposition of alpha-fluoromethylhistidine, a new histidine decarboxylase inhibitor.

August TF, Musson DG, Hwang SS, Duggan DE, Hooke KF, Roman IJ, Ferguson RJ, Bayne WF.

J Pharm Sci. 1985 Aug;74(8):871-5.

PMID:
4032273
22.

Effect of enterohepatic circulation on the pharmacokinetics of diflunisal in rats.

Lin JH, Yeh KC, Duggan DE.

Drug Metab Dispos. 1985 May-Jun;13(3):321-6.

PMID:
2861991
23.

Inhibition of histamine synthesis in vitro and in vivo by S-alpha-fluoromethylhistidine.

Duggan DE, Hooke KF, Maycock AL.

Biochem Pharmacol. 1984 Dec 15;33(24):4003-9.

PMID:
6439218
24.
25.

Biliary secretion of sulindac and metabolites in man.

Dobrinska MR, Furst DE, Spiegel T, Vincek WC, Tompkins R, Duggan DE, Davies RO, Paulus HE.

Biopharm Drug Dispos. 1983 Oct-Dec;4(4):347-58.

PMID:
6661513
26.

Inhibitors of glycolic acid oxidase. 4-Substituted 3-hydroxy-1H-pyrrole-2,5-dione derivatives.

Rooney CS, Randall WC, Streeter KB, Ziegler C, Cragoe EJ Jr, Schwam H, Michelson SR, Williams HW, Eichler E, Duggan DE, Ulm EH, Noll RM.

J Med Chem. 1983 May;26(5):700-14.

PMID:
6341589
27.

Enterohepatic circulation of sulindac and metabolites.

Dujovne CA, Pitterman A, Vincek WC, Dobrinska MR, Davies RO, Duggan DE.

Clin Pharmacol Ther. 1983 Feb;33(2):172-7.

PMID:
6822030
28.

Sulfoxide reduction. In vitro reduction of sulindac by rat hepatic cytosolic enzymes.

Ratnayake JH, Hanna PE, Anders MW, Duggan DE.

Drug Metab Dispos. 1981 Mar-Apr;9(2):85-7.

PMID:
6113122
29.

Sulindac: therapeutic implications of the prodrug/pharmacophore equilibrium.

Duggan DE.

Drug Metab Rev. 1981;12(2):325-37. Review.

PMID:
7040018
30.

Kinetics of the tissue distributions of sulindac and metabolites. Relevance to sites and rates of bioactivation.

Duggan DE, Hooke KF, Hwang SS.

Drug Metab Dispos. 1980 Jul-Aug;8(4):241-6.

PMID:
6105058
31.

An electron-capture gas chromatographic procedure for the estimation of oxalic acid in urine.

Tocco DJ, Duncan AE, Noll RM, Duggan DE.

Anal Biochem. 1979 Apr 15;94(2):470-6. No abstract available.

PMID:
464317
32.

Determination of urinary oxalic acid and of oxalate pool size by stable isotope dilution.

Duggan DE, Walker RW, Noll RM, VandenHeuvel WJ.

Anal Biochem. 1979 Apr 15;94(2):477-82. No abstract available.

PMID:
380401
33.

Enterohepatic recirculation of drugs as a determinant of therapeutic ratio.

Duggan DE, Kwan KC.

Drug Metab Rev. 1979;9(1):21-41. No abstract available.

PMID:
446267
34.

Effects of concomitant aspirin administration on the pharmacokinetics of indomethacin in man.

Kwan KC, Breault GO, Davis RL, Lei BW, Czerwinski AW, Besselaar GH, Duggan DE.

J Pharmacokinet Biopharm. 1978 Dec;6(6):451-76.

PMID:
731412
35.

Selective inhibitors of biosynthesis of aminergic neurotransmitters.

Kollonitsch J, Perkins LM, Patchett AA, Doldouras GA, Marburg S, Duggan DE, Maycock AL, Aster SD.

Nature. 1978 Aug 31;274(5674):906-8. No abstract available.

PMID:
683331
36.

Comparative disposition of sulindac and metabolites in five species.

Duggan DE, Hooke KF, Noll RM, Hucker HB, Van Arman CG.

Biochem Pharmacol. 1978;27(19):2311-20. No abstract available.

PMID:
103551
37.

2-pyridylimidazoles as inhibitors of xanthine oxidase.

Baldwin JJ, Lumma PK, Novello FC, Ponticello GS, Sprague JM, Duggan DE.

J Med Chem. 1977 Sep;20(9):1189-93.

PMID:
926119
38.

Pharmacokinetics of Sulindac.

Kwan KC, Duggan DE.

Acta Rhumatol Belg. 1977 Jul-Dec;1(3-4):168-78. No abstract available.

PMID:
756665
39.

The effects of probenecid upon the individual components of indomethacin elimination.

Duggan DE, Hooke KF, White SD, Noll RM, Stevenson CR.

J Pharmacol Exp Ther. 1977 May;201(2):463-70.

PMID:
404419
40.

Identification of the biologically active form of sulindac.

Duggan DE, Hooke KF, Risley EA, Shen TY, Arman CG.

J Pharmacol Exp Ther. 1977 Apr;201(1):8-13.

PMID:
850147
41.

Radioimmunoassay of indomethacin in biological fluids.

Hare LE, Ditzler CA, Duggan DE.

J Pharm Sci. 1977 Apr;66(4):486-9.

PMID:
558327
42.

Analysis of sulindac and metabolites by combined isotope dilution-radioimmunoassay.

Hare LE, Ditzler CA, Hichens M, Rosegay A, Duggan DE.

J Pharm Sci. 1977 Mar;66(3):414-7.

PMID:
321751
43.

The disposition of sulindac.

Duggan DE, Hare LE, Ditzler CA, Lei BW, Kwan KC.

Clin Pharmacol Ther. 1977 Mar;21(3):326-35.

PMID:
300048
44.

A stable isotope gas-liquid chromatographic-mass spectrometric assay for determining uric acid body pool size.

Walker RW, VandenHeuvel WJ, Wolf FJ, Noll RM, Duggan DE.

Anal Biochem. 1977 Jan;77(1):235-42. No abstract available.

PMID:
831573
46.

Kinetics of indomethacin absorption, elimination, and enterohepatic circulation in man.

Kwan KC, Breault GO, Umbenhauer ER, McMahon FG, Duggan DE.

J Pharmacokinet Biopharm. 1976 Jun;4(3):255-80. No abstract available.

PMID:
978392
47.

Enterohepatic circulation of indomethacin and its role in intestinal irritation.

Duggan DE, Hooke KF, Noll RM, Kwan KC.

Biochem Pharmacol. 1975 Oct 1;24(19):1749-54. No abstract available.

PMID:
823946
48.

4-Trifluoromethylimidazoles and 5-(4-pyridyl)-1,2,4-triazoles, new classes of xanthine oxidase inhibitors.

Baldwin JJ, Kasinger PA, Novello FC, Sprague JM, Duggan DE.

J Med Chem. 1975 Sep;18(9):895-900.

PMID:
1171986
49.

Bioavailability of dexamethasone. II. Dexamethasone phosphate.

Hare LE, Yeh KC, Ditzler CA, McMahon FG, Duggan DE.

Clin Pharmacol Ther. 1975 Sep;18(3):330-7.

PMID:
1100302
50.

3,5-disubstituted 1,2,3,4-triazoles, 1 new class of xanthine oxidase inhibitor.

Duggan DE, Noll RM, Baer JE, Novello FC, Baldwin JJ.

J Med Chem. 1975 Sep;18(9):900-5.

PMID:
808613

Supplemental Content

Loading ...
Support Center